KAZALD1

Across TCGA pan-cancer cohorts, KAZALD1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of KAZALD1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KAZALD1 RNA is repressed in tumor relative to normal tissue. In most cancer types KAZALD1 is over-expressed in tumor, although a few such as KIRC and HNSC show the opposite, repressed pattern.

KIRC, LIHC, and UCEC are the cancer types where KAZALD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KAZALD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.528	<.001	10	view →
LIHC	Female	II,III,IV	+1.256	<.001	9	view →
UCEC	All	II,III,IV	+2.541	<.001	8	view →
LUAD	Male	II,III,IV	+0.784	.005	6	view →
BRCA	Female	All	+0.651	<.001	6	view →
HNSC	Female	III,IV	−0.652	.027	3	view →
CHOL	All	All	+1.646	.002	2	view →
STAD	Male	IV	−1.104	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

KAZALD1–KIRC

Open the KIRC breakdown →